MorphoSys to Start Share Buy-Back Program
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys to Start Share Buy-Back Program
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced today the
decision to repurchase its own shares on the stock market. Following approval by
the Company's Supervisory Board, the Board of Management of MorphoSys AG has
resolved to acquire up to 85,000 MorphoSys shares over the stock market during
the time period from April 22, 2013 to May 10, 2013. On the basis of the current
share price (status: April 19, 2013), this would amount to around EUR 2.6
million or up to 0.36% of the share capital.
The Company intends to use the shares for its long-term incentive programs for
its management, but the shares can also be used for all purposes stated in the
authorization of the Annual General Meeting of May 19, 2011.
The relevant conditions of the shareholders' resolutions passed in the ordinary
shareholders' meeting 2011 of MorphoSys AG on the authorization to acquire and
to use its own shares shall apply. The purchase price paid per share may not be
more than 10 % higher or 20 % lower than the Company's share price determined by
the opening auction in the Xetra trading system on the day of trading.
The buy-back is to be handled independently of and uninfluenced by the Company
through an appointed bank in compliance with the safe-harbor provisions.
MorphoSys will provide regular information on the progress of the share buy-back
program on the Company's website www.morphosys.com/share-buyback.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®),
Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of
MorphoSys AG.
Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1694876/557513.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1694876]
Unternehmensinformation / Kurzprofil:
Datum: 22.04.2013 - 18:15 Uhr
Sprache: Deutsch
News-ID 251457
Anzahl Zeichen: 4773
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 213 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys to Start Share Buy-Back Program"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
